Cargando…
Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
SIMPLE SUMMARY: The majority of patients with advanced prostate cancer eventually develop bone metastases. Radium-223 has improved overall survival and relieved symptoms related to bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC). In a phase 3 trial (ERA 223),...
Autores principales: | Suominen, Mari I., Knuuttila, Matias, Sjöholm, Birgitta, Wilson, Timothy, Alhoniemi, Esa, Mumberg, Dominik, Käkönen, Sanna-Maria, Scholz, Arne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452892/ https://www.ncbi.nlm.nih.gov/pubmed/37627143 http://dx.doi.org/10.3390/cancers15164115 |
Ejemplares similares
-
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
por: Suominen, Mari I., et al.
Publicado: (2023) -
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2021) -
The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
por: Suominen, Mari I., et al.
Publicado: (2019) -
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020) -
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)